Sex and survival outcomes in patients with renal cell carcinoma
receiving first-line immune-based combinations

J 2024

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

INCORVAIA, Lorena, Fernando Sabino Marques MONTEIRO, Francesco MASSARI, Se Hoon PARK, Giandomenico ROVIELLO et. al.

Základní údaje

Originální název

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Autoři

Vydání

Cancer immunology, immunotherapy, NEW YORK, SPRINGER, 2024, 0340-7004

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.800 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00262-024-03719-0

UT WoS

001239361300007

Klíčová slova anglicky

ARON-1 study; Gender differences; Immunotherapy; Immune-based combinations; NCT05287464; Renal cell carcinoma

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 7. 2024 08:25, Mgr. Tereza Miškechová

Anotace

V originále

Background There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking. Method This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy. Results A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008). Conclusions Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.

Citovat

INCORVAIA, Lorena, Fernando Sabino Marques MONTEIRO, Francesco MASSARI, Se Hoon PARK, Giandomenico ROVIELLO, Ondrej FIALA, Zin W MYINT, Jakub KUCHARZ, Javier MOLINA-CERRILLO, Daniele SANTINI, Thomas BUTTNER, Alexandr POPRACH, Jindrich KOPECKY, Annalisa ZEPPELLINI, Martin PICHLER, Tomas BUCHLER, Renate PICHLER, Gaetano FACCHINI, Andre Poisl FAY, Andrey SOARES, Ray MANNEH, Laura IEZZI, Zsofia KURONYA, Antonio RUSSO, Maria T BOURLON, Dipen BHUVA, Jawaher ANSARI, Ravindran KANESVARAN, Enrique GRANDE, Sebastiano BUTI a Matteo SANTONI. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. Cancer immunology, immunotherapy. NEW YORK: SPRINGER, 2024, roč. 73, č. 8, s. 1-12. ISSN 0340-7004. Dostupné z: https://dx.doi.org/10.1007/s00262-024-03719-0.

@article{2416238,
   author = {Incorvaia, Lorena and Monteiro, Fernando Sabino Marques and Massari, Francesco and Park, Se Hoon and Roviello, Giandomenico and Fiala, Ondrej and Myint, Zin W and Kucharz, Jakub and MolinaandCerrillo, Javier and Santini, Daniele and Buttner, Thomas and Poprach, Alexandr and Kopecky, Jindrich and Zeppellini, Annalisa and Pichler, Martin and Buchler, Tomas and Pichler, Renate and Facchini, Gaetano and Fay, Andre Poisl and Soares, Andrey and Manneh, Ray and Iezzi, Laura and Kuronya, Zsofia and Russo, Antonio and Bourlon, Maria T and Bhuva, Dipen and Ansari, Jawaher and Kanesvaran, Ravindran and Grande, Enrique and Buti, Sebastiano and Santoni, Matteo},
   article_location = {NEW YORK},
   article_number = {8},
   doi = {http://dx.doi.org/10.1007/s00262-024-03719-0},
   keywords = {ARON-1 study; Gender differences; Immunotherapy; Immune-based combinations; NCT05287464; Renal cell carcinoma},
   language = {eng},
   issn = {0340-7004},
   journal = {Cancer immunology, immunotherapy},
   title = {Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations},
   url = {https://link.springer.com/article/10.1007/s00262-024-03719-0},
   volume = {73},
   year = {2024}
}

TY  - JOUR
ID  - 2416238
AU  - Incorvaia, Lorena - Monteiro, Fernando Sabino Marques - Massari, Francesco - Park, Se Hoon - Roviello, Giandomenico - Fiala, Ondrej - Myint, Zin W - Kucharz, Jakub - Molina-Cerrillo, Javier - Santini, Daniele - Buttner, Thomas - Poprach, Alexandr - Kopecky, Jindrich - Zeppellini, Annalisa - Pichler, Martin - Buchler, Tomas - Pichler, Renate - Facchini, Gaetano - Fay, Andre Poisl - Soares, Andrey - Manneh, Ray - Iezzi, Laura - Kuronya, Zsofia - Russo, Antonio - Bourlon, Maria T - Bhuva, Dipen - Ansari, Jawaher - Kanesvaran, Ravindran - Grande, Enrique - Buti, Sebastiano - Santoni, Matteo
PY  - 2024
TI  - Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
JF  - Cancer immunology, immunotherapy
VL  - 73
IS  - 8
SP  - 1-12
EP  - 1-12
PB  - SPRINGER
SN  - 03407004
KW  - ARON-1 study
KW  - Gender differences
KW  - Immunotherapy
KW  - Immune-based combinations
KW  - NCT05287464
KW  - Renal cell carcinoma
UR  - https://link.springer.com/article/10.1007/s00262-024-03719-0
N2  - Background There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking. Method This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy. Results A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7-44.2) in the overall study population: 40.0 months (95% CI 32.7-51.6) in males and 38.7 months (95% CI 26.4-41.0) in females (p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0-51.6, vs. 24.8 months, 95% CI 16.8-40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8-55.7, vs. 38.7 months, 95% CI 26.0-41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4-59.0, vs. 15.3 months, 95% CI 8.9-41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 - 2.57, p = 0.008). Conclusions Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.
ER  -

INCORVAIA, Lorena, Fernando Sabino Marques MONTEIRO, Francesco MASSARI, Se Hoon PARK, Giandomenico ROVIELLO, Ondrej FIALA, Zin W MYINT, Jakub KUCHARZ, Javier MOLINA-CERRILLO, Daniele SANTINI, Thomas BUTTNER, Alexandr POPRACH, Jindrich KOPECKY, Annalisa ZEPPELLINI, Martin PICHLER, Tomas BUCHLER, Renate PICHLER, Gaetano FACCHINI, Andre Poisl FAY, Andrey SOARES, Ray MANNEH, Laura IEZZI, Zsofia KURONYA, Antonio RUSSO, Maria T BOURLON, Dipen BHUVA, Jawaher ANSARI, Ravindran KANESVARAN, Enrique GRANDE, Sebastiano BUTI a Matteo SANTONI. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. \textit{Cancer immunology, immunotherapy}. NEW YORK: SPRINGER, 2024, roč.~73, č.~8, s.~1-12. ISSN~0340-7004. Dostupné z: https://dx.doi.org/10.1007/s00262-024-03719-0.

Podrobný výpis o publikaci